S
Stellaromics
A biomedical research company with its proprietary technology, unraveling complex 3D transcription and translation patterns within native biological tissue
About Stellaromics
Stellaromics is a biotechnology company at the forefront of 3D in situ multi-omic analysis. The company has developed the Pyxa platform, a technology that facilitates three-dimensional spatial multi-omics to capture the complexity of multicellular tissues. This platform is designed to serve the biomedical research community, with applications in neuroscience and cancer studies.
Read full description
The company's proprietary STARmap (Spatially-resolved Transcriptome Amplicon-Readout Mapping) technology is a key component of its platform. This technology is capable of measuring the expression of thousands of genes within a single tissue sample, providing researchers with a detailed view of cellular function and organization. By offering a three-dimensional perspective, Stellaromics aims to provide deeper insights than traditional two-dimensional spatial biology methods.
Stellaromics operates on a business model centered around providing its Pyxa platform and associated services to research institutions and pharmaceutical companies. The company generates revenue through the sale of its platform, as well as through collaborations and partnerships with research organizations. The company is backed by venture capital funding, having secured a $25 million series A round to advance its technology and expand its market reach.
At a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Natick, United States
- Employees
- 57
- Open positions
- 2
- Dealroom signal
- 86.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Feb 2025 | $80M | $320M | Stanford Technology Ventures Program · Catalyst4 | ↗ |
| SERIES AOther financing | Nov 2023 | $25M | $100M | Plaisance Capital Management | ↗ |
Growth signals
Latest recorded traffic for Stellaromics is 2.1K monthly website visits, down 44.7% over the last three months. Stellaromics's team grew 11.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Plaisance Capital Management
Catalyst4
Stanford Technology Ventures Program
Other known investors2 additional known investors
Broad Institute
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Stellaromics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Stellaromics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.